Race Oncology (ASX:RAC) share price edges higher amid patent update

Race shares have moved into the green after a rollercoaster day so far…

| More on:
Three healthcare workers look and point at at medical image

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Race Oncology Ltd (ASX: RAC) share price has been seesawing today and is now at $3.17. That's a 0.32% gain on the previous closing price.

Race shares have been as high as $3.19 and as low as $3.08 so far today. This comes after an announcement from the company regarding another patent for its Zantrene label.

Here are the details.

Sixth US patent for drug candidate Zantrene

The release notes the US Patent and Trademarks Office (USPTO) issued a new patent on Race's cancer drug candidate, Zantrene.

Zantrene works by inhibiting a particular kind of cancer growth accelerant in the body, known as the fat mass and obesity-associated protein (FTO).

Race is investigating its use in a number of complex conditions as both a substitute and complementary therapy.

As it relates to investors, the company is "pursuing outsized commercial returns for shareholders via its 'three pillar' strategy" to clinically develop Zantrene.

Race was awarded today's patent for "protection around uses of Zantrene that improve the efficacy of Zantrene treatments".

According to the company, the new patent is another plus in Zantrene's launch curve, as it further expands the therapeutic utility of the compound.

It also protects Race's ability to innovate around the flagship drug, particularly to improve patient outcomes. However, today's news has done little to spark the Race Oncology share price.

This marks the sixth granted patent of the phase 2/3 cancer drug candidate, after a recent update earlier this month regarding the fifth patent.

The precision oncology company reckons the USPTO granting a sixth patent only serves to strengthen its growing IP position for Zantrene.

Race Oncology share price snapshot

The Race Oncology share price has boasted an outsized return profile this year to date, having climbed around 80% into the green since January 1.

It has also gained around 230% in the past 12 months. That's well ahead of the benchmark S&P/ASX 200 index (ASX: XJO)'s return of around 19% over the same time.

At the time of writing, Race Oncology has a market capitalisation of $463 million.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Monash IVF shares fall 25% following second embryo incident

Its been a forgettable start to 2025 for Monash IVF shareholders.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Buying CSL shares? Meet your new board director

CSL’s new board director has spent the last 11 years in an executive role at Australia’s $240 billion Future Fund.

Read more »

A man sits in contemplation on his sofa looking at his phone as though he has just heard some serious or interesting news.
Technology Shares

Up 60% in two months, is it too late to buy Pro Medicus shares?

Pro Medicus has been delivering solid returns for years. Can the trend continue?

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why this ASX All Ords stock is jumping 9% today

What has put a rocket under this stock on Friday? Let's find out.

Read more »

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »

Two brokers analysing stocks.
Healthcare Shares

Why does Macquarie think Fisher & Paykel shares are a buy?

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares have been on form over the past 12 months. During this…

Read more »